JAMES WELSH to Immunotherapy
This is a "connection" page, showing publications JAMES WELSH has written about Immunotherapy.
Connection Strength
4.274
-
Is Single-Site Radiation Therapy Enough to Augment the Immune System and Enhance Immunotherapy for Metastatic Disease? Semin Radiat Oncol. 2024 Jul; 34(3):272-275.
Score: 0.359
-
Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases. Front Immunol. 2021; 12:812210.
Score: 0.301
-
Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Semin Radiat Oncol. 2021 07; 31(3):217-226.
Score: 0.291
-
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021 05; 9(5):467-475.
Score: 0.278
-
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020 10; 8(2).
Score: 0.277
-
Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun. 2020 09 24; 11(1):4840.
Score: 0.276
-
Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):196-203.
Score: 0.265
-
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer. 2019 09 04; 7(1):237.
Score: 0.257
-
Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States. J Immunother. 2019 Feb/Mar; 42(2):55-64.
Score: 0.247
-
Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1141-1148.
Score: 0.234
-
Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014 Sep; 2(9):831-8.
Score: 0.181
-
Hybridizing mechanistic modeling and deep learning for personalized survival prediction after immune checkpoint inhibitor immunotherapy. NPJ Syst Biol Appl. 2024 Aug 14; 10(1):88.
Score: 0.090
-
Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection. JCI Insight. 2023 06 22; 8(12).
Score: 0.084
-
NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model. Front Immunol. 2022; 13:1022011.
Score: 0.080
-
Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. Front Immunol. 2022; 13:984318.
Score: 0.080
-
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. Elife. 2021 11 09; 10.
Score: 0.075
-
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021 09; 162:60-67.
Score: 0.073
-
Use of Multi-Site Radiation Therapy for Systemic Disease Control. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):352-364.
Score: 0.069
-
Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy. Radiother Oncol. 2020 09; 150:114-120.
Score: 0.068
-
Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. Sci Adv. 2020 05; 6(18):eaay6298.
Score: 0.067
-
Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer. 2019 04; 58(4):244-253.
Score: 0.062
-
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018 11 23; 6(1):128.
Score: 0.061
-
Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies. Eur Urol Oncol. 2019 02; 2(1):79-87.
Score: 0.061
-
Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacol Ther. 2019 03; 195:162-171.
Score: 0.061
-
Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy. Immunotherapy. 2018 08; 10(10):851-0.
Score: 0.060
-
Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):593-600.
Score: 0.059
-
Radiation therapy and immunotherapy: what is the optimal timing or sequencing? Immunotherapy. 2018 02 01; 10(4):299-316.
Score: 0.058
-
Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer J. 2016 Jul-Aug; 22(4):257-66.
Score: 0.052
-
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol. 2024 04; 193:110121.
Score: 0.022
-
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881.
Score: 0.021
-
The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy. Front Immunol. 2023; 14:1172931.
Score: 0.021
-
Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): A systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy. Radiother Oncol. 2022 12; 177:81-94.
Score: 0.020
-
Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance. Front Immunol. 2022; 13:1033642.
Score: 0.020
-
Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates. Cancer Commun (Lond). 2021 11; 41(11):1086-1099.
Score: 0.019
-
A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. Nat Biomed Eng. 2021 04; 5(4):297-308.
Score: 0.018
-
Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J. 2016 Mar-Apr; 22(2):130-7.
Score: 0.013